Vulnerable substrate and multiple ion channel disorder in a diseased heart will be new targets for antiarrhythmic therapy

Acta Pharmacologica Sinica

Volumn 21, Issue 4, 2000, Pages 289-295

  Dai, De Zai ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Anti arrhythmic agents; CPU 86017; Hypertrophy; Ion channels; Levothyroxin; Myocardial infarction; Norepinephrine

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR; CPU 86017; ION CHANNEL; LEVOTHYROXINE; NORADRENALIN; POTASSIUM CHANNEL; SODIUM CHANNEL; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ANTIARRHYTHMIC ACTIVITY; ENZYME ACTIVITY; GENE MUTATION; HEART ARRHYTHMIA; HEART DISEASE; HEART INFARCTION; HEART VENTRICLE HYPERTROPHY; HUMAN; LONG QT SYNDROME; PATHOGENESIS; REVIEW;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; BERBERINE; CARDIOMEGALY; HUMANS; ION CHANNELS; LONG QT SYNDROME; MYOCARDIAL INFARCTION; NOREPINEPHRINE; SUPEROXIDE DISMUTASE;

EID: 0034050276     PISSN: 02539756     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Bayes de Luna A, Coumel P, Leclercq JF. Ambulatory sudden cardiac death, mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J 1989; 117: 151-9.
2. Lucchesi BR. Sudden coronary death: Pharmacological interventions for the prevention of ventricular fibrillation. Trends Pharmacol Sci 1984; 5: 145-8.
3. Praff CM, Waldo AL, Camm AJ. Can antiarrhythmic drugs survive survival trials? Am J Cardiol 1998; 81(6A): 24D-34D.
4. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial Investigators. N Engl J Med 1989; 321: 406-12.
5. The Sicilian gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. Circulation 1991; 81: 1831-51.
6. Colatsky TJ. The Sicilian Gambit and antiarrhythmic development. Cardiovasc Res 1992; 26: 562-5.
7. Dai DZ. New Class III antiarrhythmic agents and its perspective for development. Chin J Clin Pharmacol 1998; 14: 181-4.
8. Colatsky TJ. Antiarrhythmic drugs: where are we going? PharmNews 1995; 2: 17-23.
9. Guerra PG, Talajic M, Roy D, Dubuc M, Thibault B, Nattel S. Is there a future for antiarrhythmic drug therapy? Drugs 1998; 56: 767-81.
10. Van Gelder IC, Brugemann J, Crijns HJ. Current treatment recommendations in antiarrhythmic therapy. Drugs 1998; 55: 331-46.
11. Dai DZ, Rong P, Shi ZJ, Wang LY, Dai Y, Huang J, et al. Noradrenaline depletion following myocardial infarction. Chin J Physiol Sci 1987; 3: 429-32.
12. Dai DZ, Ge J, Zhang LH, Jin L. Influences of propranolol on uptake and loss of norepinephrine in tissues in rats. Acta Pharmacol Sin 1987; 8: 519-22.
13. Dai DZ, Kuang LX, Chen L, Huang ML, Zhang DL, Zhang XA. Influence of propranolol withdrawal on the induction of sudden death in chronically infarcted rats by isoproterenol challenge. Acta Pharmacol Sin 1987; 8: 242-7.
14. Rong P, Dai DZ, Zhang JE. Global depletion of myocardial norepinephrine and ATP after left coronary artery occlusion in rats. Acta Pharmacol Sin 1992; 13: 333-7.
15. Roden DM, Lazzara R, Rosen M, Schwartz PJ, Towbin J, Vincent M, et al. Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. Circulation 1996; 91: 1996-2012.
16. Zeng J, Rudy Y. Early after depolarization in cardiac myocytes: mechanism and rate dependence. Biophys J 1995; 68: 949-61.
17. Curtis MJ. Torsades de pointes: arrhythmia, syndrome, or chimera? A perspective in the light of the Lambeth Conventions. Cardiovasc Drugs Ther 1991; 5: 191-200.
18. Grog WJ, Gibson KJ, McAnulty JH, Maylie JG. Beta-adrenergic blocking property of d, l-sotalol maintain Class III efficacy in guinea pig ventricular muscular after isopreterenol. Circulation 1995; 91: 262-4.
19. Sun ZH, Awan H, Viitasalo M, Toivonen L. Effects of epinephrine and phenylephrine on QT interval dispersion in congestive long QT syndrome. J Am Coll Cardiol 1998; 31: 1400-5.
20. Williamson AP, Seifen E, Lindemann JP, Kennedy RH. The positive inotropic effect of alphal A-adrenoceptor stimulation is inhibited by 4-aminopyridine. Eur J Pharmacol 1996; 301: 73-80.
21. + current in rabbit ventricular myocytes. J Physiol(Lond) 1991; 441: 673-84.
22. Dai DZ, An LF, Huang DY, Sun RY. Orthogonal analysis of aggravating effects of α- and β- agonists and leukocytes on reperfusion-induced arrhythmias and ventricular fibrillation in Langendorff's rat heart. Acta Pharmacol Sin 1996; 17: 145-8.
23. Qin DY, Zhang ZH, Caref EB, Boutjdir M, Jain P, EI-Sherif N. Cellular and ionic basis of arrhythmias in post-infarction remodeled ventricular myocardium. Circ Res 1996; 79: 461-73.
24. Dai DZ, Zong JG, Lei HU, Bai MQ, Rong P. Changes of superoxide dismutase, malondialdehyde, creatine phosphokinase in non-infarcted zone of an infarcted heart in rats and drug treatment. J China Pharm Univ 1995; 26: 291-6.
25. Dai DZ, Rong P, Shen W. Effects of tetra-hydroberberine derivatives on the morphological changes of acute myocardial infarction in rats. J China Pharm Univ 1989; 20: 278-82.
26. Lu HR, Yu F, Dai DZ, Remeysen P, De Clerck F. Reduction in QT dispersion and ventricular arrhythmias by ischaemic preconditioning in anaesthetized, normotensive and spontaneously hypertensive rats. Fundam Clin Pharmacol 1999; 13: 445-51.
27. Kass RS, Davies MP. The role of ion channels in an inherited heart disease: molecular genetics of the long QT syndrome. Cardiovasc Res 1996; 32: 443-51.
28. Yang P, Armstrong M, Dai DZ, Luyten W. The study of hMINK gene by PCR-SSCP analysis. Hereditas (Beijing) 1999; 21: 29-31.
29. Li X, Xu J, Li M. The human 1261 mutation of the HERG potassium channel results in a truncated protein that contains a subunit interaction domain and decreases the channel expression. J Biol Chem 1997; 272: 705-8.
30. Bennet PB, Yazawa K, Makita N, George AL Jr. Molecular mechanism for an inherited cardiac arrhythmia. Nature 1995; 376: 1136-44.
31. Kambouris NG, Nuss HB, Johns DC, Tomaselli GF, Marban E, Balser JR. Phenotypic characterization of a novel long-QT syndrome mutation (R1623Q) in the cardiac sodium channel. Circulation 1998; 97: 610-4.
32. YangP. Part 1: Molecular biologica basis of congenital long QT syndrome: complete screening of HERG and hMINK genes by PCR-SSCP analyses [dissertation]. Nanjing: China Pharm Univ; 1999.
33. Wickenden AD, Kaprielian R, Kassiri Z, Tsoporis JN, Tsushima R, Fishman GI, et al. The role odf action potential prolongation and altered intracellular calcium handling in the pathogenesis of the heart failure. Cardiovasc Res 1998; 37: 312-23.
34. Yu F, Dai DZ, An LF, Guo XF. Heart hypertrophy induced by levothyroxin aggravates ischemic lesions and reperfusion arrhythmias in rats. Acta Pharmacol Sin 1997; 18: 71-4.
35. DaiDZ, Hu HI, Yang DM, Hao XM, Zhang GQ, Zhou GQ, et al. Chronic levothyroxin treatment is associated with ion channel abnormalities in cardiac and neuronal cells. Clin Exp Pharmacol Physiol 1999; 26: 819-21.
36. MA YP. Part 1: Ion channel mechanisms of arrhythmias caused by hypertrophied cardiac myocytes: changes of sodium and potassium ion channels in hypertrophied cardiac myocytes induced by L-thyroxin[dissertation]. Nanjing: Chin Pharm Univ; 1999.
37. Dai DZ. Patterns and characteristics of ion channel disease inducing cardiac arrhythmias and drug interventions, Prog Pharm Sci 1998; 22: 148-52.
38. 2+-ATPase activity induced by L-thyroxin in rats. Chin J Pharmacol Toxicol 1995; 9: 228-30.
39. 2+-ATPase activity eleva-tion. Acta Pharmacol Sin 1996; 17: 516-8.
40. + channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation 1995; 92: 3381-6.
41. Bayes de Luna A, Coumel P, Leclercq JF. Ambulatory sudden death: Mechanisms of production of fatal arrhythmias on the basis of data from 157 cases. Am Heart J 1989; 117: 151-9.
42. Katz AM. Selectivity and toxicity of antiarrhythmic drugs: molecular interactions with ion channels. Am J Med 1998; 104: 179-95.
43. Dai DZ. The antiarrhythmic activity of protoberberines in relation to blockade on ion channel. Ion Channels Modulators 1997; 2: 383-90.
44. Dai DZ, An LF, Wang YQ, Huang J, Zhang H, Dai D, et al. CPU 86017 suppression of arrhythmias induced by ischemia/reperfusion, ouabain, aconitine, and elevation of ventricular fibrillatory threshold. Drug Dev Res 1996; 39: 184-90.
45. Dai DZ, Yu F, Li HT, Tang YQ, An LF, Huang WL, et al. Blockade on sodium, potassium, and calcium channels by a new antiarrhythmic agent CPU 86017. Drug Dev Res 1996; 39: 138-46.
46. Fermini B, Jurkiewicz NK, Jow B, Guinosso PJ Jr , Baskin EP, Lynch JJ Jr, et al. Use-dependent effects of the class III antiarrhythmic agent NE-10064 (azimilide) on cardiac repolarization: block of delayed rectifier potassium and L-type calcium currents. J Cardiovasc Pharmacol 1995; 26: 259-71.
47. Singh BN. Antiarrhythmic drugs: a reorientation in light of recent developments in the control of disorders of rhythm. Am J Cardiol 1998; 81 (6A): 3D-13D.